dapagliflozin + empagliflozin + ertugliflozin + sotagliflozin

This is a hypothetical combination drug consisting of four sodium-glucose co-transporter 2 (SGLT2) inhibitors—dapagliflozin, empagliflozin, ertugliflozin, and sotagliflozin. All four are oral small molecule agents primarily used for the management of type 2 diabetes mellitus by inhibiting SGLT2 in the proximal renal tubules, thereby reducing glucose reabsorption and promoting glycosuria to lower blood glucose levels[1][3]. Sotagliflozin is unique among them as it also inhibits SGLT1 in the intestine, delaying glucose absorption and further reducing postprandial blood sugar[4][5]. These drugs have demonstrated additional benefits including reduction in cardiovascular events, improvement in heart failure outcomes, and renal protection. Each agent has been studied individually or as part of dual/triple therapy regimens; however, there is no evidence that a fixed-dose quadruple combination product containing all four exists or has been clinically tested.